On April 24, 2025 PharmaMar Group (MSE: PHM) reported 19% growth in recurring revenues in the first quarter of 2025 (Press release, PharmaMar, APR 24, 2025, View Source [SID1234652109]). This revenue, which is the sum of net sales plus royalties received from our partners, amounted to €37.8 million as of March 31st, 2025. This increase was mainly driven by the good performance of lurbinectedin revenues in both Europe and the US.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As of March 31st, 2025, total oncology revenues increased by 22% to €23.1 million, compared with €19.0 million in the same period of last year. This increase was due to the positive performance of lurbinectedin revenues in Europe, where revenues recorded under the compassionate use program – mainly in France – rose 26% to €8.0 million, compared to €6.3 million as of March 31, 2024. In addition, commercial sales of Zepzelca in Switzerland amounted to €4.3 million in the first quarter of the year, compared with €4.2 million in the same period of 2024.

Also, raw material sales of both Yondelis (trabectedin) and lurbinectedin to our partners amounted to €5.7 million, representing an increase of 72.3% compared to the €3.3 million recorded in the same period of the previous year.

Sales of trabectedin in Europe through March 31st, 2025, remained stable at €5.2 million.

At the end of the first quarter of 2025, oncology royalty revenues amounted to €14.7 million, an increase of 16% over the same period of the previous year. This growth was led by royalties received from our partner Jazz Pharmaceuticals for lurbinectedin sales in the US, which increased by 9% to €12.7 million[1].

In addition to the royalties received from Jazz Pharmaceuticals through March 31st, 2025, royalties on trabectedin sales from our partners in the U.S. and Japan totaled €2.0 million, almost double the €1.1 million recorded in the first quarter of 2024.

With regard to non-recurring revenues from licensing agreements, at the end of the first quarter of 2025, these amounted to €1.0 million, compared with €6.0 million as of March 31st, 2024. Both figures come from the recognition as revenue of a portion of the deferred revenue from the 2019 agreement signed with Jazz Pharmaceuticals in relation to Zepzelca.

In the current fiscal year, the annual imputation of income related to this agreement is estimated at €4 million, while the total for the previous year was approximately €23 million. Of the total €300 million of income received in 2020 in connection with this agreement, 93% has already been taken to income in recent years. The remaining 7% will be recognized in future fiscal years.

As a result, PharmaMar Group reported 2% growth in total revenues in the first quarter of 2025, to €38.9 million.

PharmaMar Group R&D expenditure amounted to €21.3 million, 22% less than in the first quarter of 2024.

Of total R&D expenditure in the period, the oncology segment accounted for €19.8 million, compared with €24.6 million at March 31st, 2024. This change is mainly due to the completion of recruitment in December 2024 for the LAGOON Phase III clinical trial with lurbinectedin in small-cell lung cancer.

In the RNAI segment 1.5 million was allocated, compared with €2.6 million in the same period of the previous year. This variation is due to the completion in the first months of 2024 of the PIVO1 phase III clinical trial with tivanisiran for dry eye disease.

In addition, the Company continues to invest in the clinical development of three molecules at earlier stages. Two Phase II clinical trials are underway with ecubectedin, as well as Phase I clinical trials with PM534 and PM54, all for the treatment of solid tumors.

EBITDA improved, compared to the same period of the previous year, standing at- € 1.1 M compared to € -2.7 M in the first quarter of 2024.

Net income, as of March 31st, 2025, stands at -€3.9 M compared to a profit of € 2.3 as of March 31st, 2024. This difference is due to the positive financial results recorded in March 2024 in addition to a positive income tax balance.

At March 31st 2025, the PharmaMar Group recorded a cash and cash equivalents balance of €142.2 million, with total financial debt of €48.5 million. As a result, the net cash position at end of the first quarter of 2025 was €93.7 million.

On April 24, 2025 Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") reported a €14,999,998.59 capital increase subscribed by Sanofi (Press release, Innate Pharma, APR 24, 2025, View Source [SID1234652125]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As announced on April 23, 2025, and given the satisfactory market conditions, Sanofi has agreed to subscribe to 8,345,387 new ordinary shares of Innate, at a price of €1.7974 per share, representing a total capital increase of €14,999,998.59 (€417,269.35 in nominal amount and €14,582,729.24 of issue premium).

The subscription price of €1.7974 per share (€0.05 in nominal amount and €1.7474 of issue premium) is equal to the daily volume-weighted average price of the ordinary shares of Innate on the regulated market of Euronext in Paris on April 23, 2025.

"We welcome Sanofi’s strategic investment in Innate, which further reinforces the strength of our collaboration. The proceeds from this capital increase will be used for general corporate purposes, including extending our cash runway to support continued pipeline execution and long-term value creation", said Jonathan Dickinson, Chief Executive Officer of Innate Pharma.

This capital increase is to be completed pursuant to the 22nd resolution of the combined general meeting of shareholders of Innate held on 23 May 2024.

Closing of the capital increase is expected to take place on April 25, 2025. The newly issued shares will be admitted to trading on the regulated market of Euronext in Paris on the same day.

The tables below set out the Company’s shareholding, based on the information available to Innate as of the date of this press release, before and after the closing of the capital increase:

Before closing

Shareholder

Nb of Shares*

%

Nb of voting rights†

%

Novo Nordisk A/S

9,817,546

11.71%

9,817,546

11.60%

Medimmune Limited

7,485,500

8.93%

7,485,500

8.85%

Bpifrance Participations

6,389,406

7.62%

6,389,406

7.55%

Members of the Executive Board, Supervisory Board and Leadership Team

846,944

1.01%

911,444

1.08%

Treasury shares

18,575

0.02%

0

0%

Public

59,286,440

70.71%

59,995,085

70.92%

Total

83,844,411

100%

84,598,981

100%

After closing

Shareholder

Nb of Shares*

%

Nb of voting rights†

%

Novo Nordisk A/S

9,817,546

10.65%

9,817,546

10.56%

Sanofi-Aventis Participations

8,345,387

9.05%

8,345,387

8.98%

Medimmune Limited

7,485,500

8.12%

7,485,500

8.05%

Bpifrance Participations

6,389,406

6.93%

6,389,406

6.87%

Members of the Executive Board, Supervisory Board and Leadership Team

846,944

0.92%

911,444

0.98%

Treasury shares

18,575

0.02%

0

0%

Public

59,286,440

64.31%

59,995,085

64.55%

Total

92,189,798

100%

92,944,368

100%

On April 24, 2025 Hoffmann-La Roche reported the company continues good momentum into 2025 with 6% (CER) sales growth in the first quarter (Press release, Hoffmann-La Roche, APR 24, 2025, View Source [SID1234654044]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On April 24, 2025 Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company, reported the availability of a new assay designed to advance antibody-drug conjugate (ADC) development in breast cancer (Press release, Akoya Biosciences, APR 24, 2025, View Source [SID1234652094]). The new assay will be featured alongside customer-generated real-world data from the PhenoCode Discovery IO60 panel—Akoya’s flagship ultrahigh-plex immuno-oncology solution—at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) 2025 Annual Meeting, taking place April 25–30 in Chicago, Illinois.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

New ADC Assay: Advancing Breast Cancer Precision

The emergence of HER2- and TROP2-targeting ADCs—such as those used in the DESTINY, ASCENT, and TROPiCS trials—have transformed breast cancer treatment while introducing greater complexity in therapeutic decision-making. Akoya’s newly launched multiplex immunofluorescence (mIF) panel is designed to address these challenges by enabling more precise patient selection within established breast cancer subtypes.

This ADC-focused panel includes HER2, TROP2, Ki-67, ER/PR, and a proprietary membrane-localization cocktail. It allows for simultaneous quantification of ADC target expression with precise subcellular localization, providing:

Normalized protein expression
Membrane/cytoplasmic expression ratios
Comparative analysis with standard-of-care IHC biomarkers
Now available through Akoya’s Advanced Biopharma Services (ABS), the ADC panel includes comprehensive support—from assay customization to tissue staining, high-resolution imaging, image analysis, and reporting. ABS is purpose-built to accelerate the path from translational discovery to IUO and IVD, with capabilities anchored in:

A CLIA-certified laboratory for clinical-grade assay development
Integrated imaging and analysis workflows for multiplexed biomarker quantification
A clinical trial site and global CRO network for end-to-end study support
The panel is optimized for:

Identifying HER2-low and TROP2-high patients in clinical trial cohorts
Resolving membrane versus cytoplasmic marker expression—critical for ADC efficacy
Delivering consistent, quantitative scoring of each ADC marker
"Multiplexing key targets in context with state-of-the-art membrane resolution is a catalyst for designing precise ADC combination strategies," said Pascal Bamford, Chief Clinical Officer at Akoya. "Our goal is to equip translational and clinical teams with assays that reflect the complexity of the tumor microenvironment while preserving clinical relevance."

Real-World Impact of IO60: Proven in the Field

Originally launched at SITC (Free SITC Whitepaper) 2024, the PhenoCode Discovery IO60 panel remains the fastest ultrahigh-plex spatial proteomics solution for immuno-oncology research. At AACR (Free AACR Whitepaper) 2025, one of Akoya’s customers will present real-world data generated using IO60, showcasing its power in:

Deep immune phenotyping
Tumor microenvironment (TME) profiling
Translating biomarker discovery across oncology pipelines
"Seeing our partners generate impactful insights using IO60 is the strongest validation of our platform’s potential," said Brian McKelligon, Chief Executive Officer of Akoya. "This is how spatial biology becomes translational—by helping researchers get closer to patient-relevant outcomes."

Visit Akoya at AACR (Free AACR Whitepaper) 2025 – Booth #3045

Both innovations—the ADC-focused breast cancer panel and customer-generated data using IO60—will be featured at Booth #3045, where Akoya will highlight the full potential of spatial biology in translational research. Visit us to explore the PhenoCode panel portfolio, meet with our scientific team, and experience our latest innovations firsthand.

What to Look Forward To:

Live Atlas Demo with Enable Medicine – Translating spatial data into actionable insights: April 27 | 4:30–5:00 PM | Akoya Booth #3045
Spotlight Theatre Presentation: From Discovery to Translation: Scaling Spatial Biology for Oncology Breakthroughs: April 28 | 3:00–4:00 PM | Spotlight Theater A – South Hall A
CDx Strategy Discussion with Clinical Experts: April 28 | 4:15–5:00 PM | Akoya Booth #3045
Early access opportunities to Akoya’s newest translational panels and biopharma service offerings
For more information about Akoya’s AACR (Free AACR Whitepaper) 2025 presence, visit: View Source

On April 24, 2025 PharmaMar (MSE:PHM) a global leader in the research, development, and commercialization of marine-derived oncology therapies, reported it will be present at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper), that will take place between the 30th of May and the 3rd of June in Chicago, U.S.A (Press release, PharmaMar, APR 24, 2025, View Source [SID1234652110]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Included among the key presentations an oral abstract of the Phase 3 IMforte trial. "Statistically significant and clinically meaningful progression-free survival (PFS) and overall survival (OS) data for lurbinectedin (Zepzelca) in combination with atezolizumab (Tecentriq) underscore potential of first line maintenance therapy for extensive stage small cell lung cancer (ES-SCLC), a much-needed advancement for patients", commented Javier Jiménez, Chief Medical Officer of PharmaMar.

The Company also will host an investor webcast on June 12th to review Phase 3 IMforte data being presented at this year’s ASCO (Free ASCO Whitepaper) Annual Meeting. The webcast will include commentaries from leading European experts in small cell lung cancer. The webcast can be accessed at View Source Additional details will be provided prior to the webcast.

The full list of PharmaMar or partner-supported presentations at the 2025 ASCO (Free ASCO Whitepaper) Annual Meeting are:

PRODUCT TITLE LEAD AUTHOR ABSTRACT
Zepzelca (lurbinectedin) Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the Phase 3 IMforte trial Luis G. Paz-Ares, MD, PhD TYPE: Oral Abstract SESSION: Lung Cancer— Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers ABSTRACT: 8006 DATE: June 2nd, 2025 (03:00 PM- 06: PM CDT)
Safety and Efficacy of Lurbinectedin Plus Atezolizumab as Second-Line Treatment for Advanced Small-Cell Lung Cancer: Results of the 2SMALL Phase 1/2 Study (NCT04253145) Santiago Ponce, MD, PhD TYPE: Rapid Oral Abstract SESSION: Lung Cancer— Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers ABSTRACT: 8013 DATE: June 1st, 2025 (04:30 PM- 06:00 PM CDT)
Evaluation of combination of lurbinectedin plus atezolizumab in humanized mouse model Antonio Calles, MD, PHD TYPE: e-poster ABSTRACT: e14614 DATE: May 22nd, 2025 (05:00 PM CDT)